According to Nova one advisor, the global Hyperpigmentation Disorders Treatment market size is expected to hit around USD 32.04 billion by 2030 from valued at USD 10.2 billion in 2021 and growing at a CAGR of 12% from 2022 to 2030.
According to Nova one advisor, the global Hyperpigmentation Disorders Treatment market size is expected to hit around USD 32.04 billion by 2030 from valued at USD 10.2 billion in 2021 and growing at a CAGR of 12% from 2022 to 2030.
Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7087
The pigmentation biology has made considerable strides over the decades, anchored broadly by evolution, developmental biology, and genetics. A significant percentage of all dermatological consultations in a number of countries around the world is motivated by cutaneous hyperpigmentations, with most common complaints between 15 and 30 years of age, regardless of color, gender, and skin.
Hyperpigmentations are a group of diseases that can be acquired or congenital, and the symptoms are associated with alterations in the melanin pigment. Key group of disorders that have been propelling revenues in the hyperpigmentation disorders treatment market are postinflammatory hyperpigmentation, solar lentigines, melasma, ephelides (or freckles), and macules. Various treatments either as standalone or a combination of any two or more have been researched for the treatment of hyperpigmentation. Melasma and vitiligo are by far the most common disorders. Most of the conditions appear to be benign but are aesthetically distressing condition.
Report Scope of the Hyperpigmentation Disorders Treatment Market
| Report Coverage | Details |
| Market Size | USD 32.04 Billion by 2030 |
| Growth Rate | CAGR of 12% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Treatment Type, Disease Indication And Region |
| Companies Mentioned | Vivier Pharma, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, EpiPharm AG, Pierre Fabre, SkinCeuticals, Galderma S.A., ALLERGAN, and Bayer AG. |
Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7087
Melasma Highly Lucrative Segment in Hyperpigmentation Disorders Treatment Market
A number of histological and immunohistochemical studies have expanded the researchers’ understanding of the pathogenesis of melasma, thus enriching the landscape of the hyperpigmentation disorders treatment market. Some of the key treatment avenues are topical hydroquinone (HQ), retinoic acid (RA), glycolic acid (GA) (double combination), and topical corticosteroid (triple combination) in double as well as triple combinations. On the back of R&D on these treatment avenues, the melasma was the leading disease indication segment in 2021.
It is predominant in women but is also significant in men across all ethnic and racial groups. This is prevalent in populations exposed to UV rays. In addition to UV exposure, various causative factors are involved. The demand for treatments is high in Asia Pacific, notably in Asian nations. A number of studies have been done to assess the demand in China, India, and Korea. Several studies have been found high prevalence of hyperpigmentation disorders in India, mainly due to prevalent sun-exposed environments. In the country, melasma can be attributed to or exacerbated by UV exposures. Upcoming therapies for melasma are likely to target prospects in this hyperpigmentation disorders treatment market and might open lucrative avenues. Advances in molecular genetics of human pigmentation disorders are enriching the landscape.
Other causes are estrogen levels, genetic predisposition, and phototoxic drugs; genetic predisposition might also play a role in causing melasma.
Effectiveness of Laser Therapies in Hyperpigmentation Disorders Treatment Market Underpin High Acceptance Among Patients
The demand for treatments of post-inflammatory hyperpigmentation (PIH) is a key accelerant for new avenues in the hyperpigmentation disorders treatment market. The prevalence of people with higher skin phototypes. Despite a large body of studies on PIH pathogenesis, currently there is an unmet need, which is expected to be capitalized by emerging and established players in the global hyperpigmentation disorders treatment market. A number of formulations such as hydroquinone, tretinoin, and dexamethasone are being explored to bridge this gap.
The growing effectiveness of laser therapies in the treatment of hyperpigmentation, such as dark circles or periorbital hyperpigmentation (POH), has generated massive revenue potential in the hyperpigmentation disorders treatment market. The patient’s acceptance of laser therapies has increased in recent years. Key of them are QS ruby laser-based treatments. The prevalent use of fractional laser photothermolysis in the treatment of disorders is a key factor bolstering the sales revenues in the hyperpigmentation disorders treatment market.
Over the years, new data on hyperpigmentation disorders have emerged, and still continue to enrich the landscape of the hyperpigmentation disorders treatment market. Subsequently, systemic use of corticosteroids, griseofulvin, antibiotics, isoniazid, antimalarials, psychotherapy, and phototherapy have boosted the hyperpigmentation disorders market.
Apart from the laser therapy, topical depigmenting agents have been extensively publicised in the hyperpigmentation disorders treatment market. These drugs aim at reducing the amount of melanin content. Topical drugs have been publicised in the treatment of cervical idiopathic poikiloderma or poikiloderma of Civatte (PC). The chronic nature of PC is a key driver for the need.
Various dermatology companies are harnessing the potential of several topical agents in newly launched products in the hyperpigmentation disorders treatment market. Of note, they have extensively marketed hydroquinone (HQ), a hydroxyphenol, for the treatment of PIH. In recent years, more studies have been done particularly in relation to developing topical retinoids for the treatment of melasma and actinic lentigines. Popular agents in some of the recent array of products in the market include soy extracts, mulberroside F, licorice extract, N-acetyl glucosamine, resveratrol, rucinol,niacinamide, and dioic acid.
Asia Pacific Expected to Gain Share in Hyperpigmentation Disorders Treatment Market
The various regional markets are Europe, North America, Asia Pacific, the Middle East & Africa, and Latin America. Of these, Asia Pacific held a major share of the global hyperpigmentation disorders treatment market in 2017. The Asia Pacific hyperpigmentation disorders treatment market is anticipated to gain share by the end of the forecast period. New revenue streams are expected to emerge from the economies of the Middle East, Latin America, and Africa.
Some of the prominent players in the Hyperpigmentation Disorders Treatment Market include:
Vivier Pharma, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, EpiPharm AG, Pierre Fabre, SkinCeuticals, Galderma S.A., ALLERGAN, and Bayer AG.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Hyperpigmentation Disorders Treatment market
Treatment Type
- Topical Drugs
- Laser Therapy
- Chemical Peels
- Microdermabrasion
- Phototherapy
- Others
Disease Indication
- Melasma
- Post-inflammatory Hyperpigmentation
- Solar Lentigines
- Others
End-user
- Hospitals
- Aesthetic Clinics & Dermatology Centers
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Hyperpigmentation Disorders Treatment industry analysis from 2022 to 2030 to identify the prevailing Hyperpigmentation Disorders Treatment industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Hyperpigmentation Disorders Treatment industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Hyperpigmentation Disorders Treatment industry trends, key players, market segments, application areas, and market growth strategies.
Full Report is Ready | For Purchase Inquiry@
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/